The Committee of Atomic and Energy Supervision and Control of the Ministry of Energy of the Republic of Kazakhstan announced the approval of three country’s national projects by the Governors’ Board of the International Atomic Energy Agency (IAEA). One of the approved national projects is a project initiated and developed by the Nuclear Medicine Center of the Medical Center Hospital of the President’s Affairs Administration of the Republic of Kazakhstan.
The project’s topic is the development and implementation of a comprehensive safety and quality program for radioactive pharmaceuticals production centers under the proper production practice in the Republic of Kazakhstan.
The significance of this project has a key role in the diagnosis of cancer and precisely that nosology that was not previously diagnosed by nuclear medicine in our country, such as neuroendocrine cancer, low-metabolic brain cancer, prostate cancer, etc.
It should be noted that imaging in the field of nuclear medicine can be compared with unique nanotechnologies, where the cellular level of the disease and the assessment of the primary tumor can be studied and visualized, as well as assessing the effectiveness of the treatment, opens up a new concept for diagnosis and evaluation of therapy, combining personalized diagnosis of the patient.
The successful implementation of such a significant project will increase the production of a wide range of radiopharmaceuticals, improve the quality of medical care, reduce the time for diagnosis of diseases, reduce mortality, increase overall survival and improve the quality of patients’ life; it will also bring the development of nuclear medicine in Kazakhstan to the world level.
